Volume 2, Issue 1 (2021)
- *Corresponding Author:
- Chloé Venuto
Dermatology, Le Mans hospital, 194 avenue Rubillard, 72100 Le Mans, France.
Received date: May 31, 2021; Accepted date: June 11, 2021; Published date: June 18, 2021
Citation: Venuto C, Piccoli G, Andrianjafy C, Terzolo E, Maillard H. Clinical Practice Survey Regarding Management of Apremilast-Related Diarrhoeas’ in Patients with Psoriasis. J Dermatol Venereol. 2021;2(1):15-19.
Copyright: © 2021 Venuto C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Psoriasis affects about 2% of the population. Apremilast is the first oral phosphodiesterase 4 (PDEA4) inhibitor marketed in Europe. Diarrhoea is the most frequent side effect. No guideline on apremilastinduced diarrhoea management is currently available. We reviewed the literature and surveyed the current practices of dermatologists in France.
We sent via a French network (ResoPso) a questionnaire to hospital and private practice dermatologists. 90% of the dermatologists offer a symptomatic treatment, 10.2% non-pharmacologic interventions, 64.6% a combination of the two. 6.1% of the dermatologists definitively stop apremilast, 74% prescribe racecadotril as a first-line symptomatic treatment.
Diarrhoea due to apremilast affects 15% of patients, its pathophysiology is secretory. It is important to grade its severity and treat its complications. The first treatment step is dietary advice, followed by the prescription of racecadotril. We can also reduce the dose. After discontinuation and reversal of diarrhea, the treatment can be restarted with increasing doses.
Psoriasis; Therapeutic; Apremilast; Diarrhoea.